Below, we take a look at Icosavax, Inc. (ICVX), a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects ...

Seattle-based Icosavax, a spin-out from the University of Washington’s Institute for Protein Design, will be acquired by biotech giant AstraZeneca for up to $1.1 billion. The pending acquisition ...

Not content with taking on the respiratory syncytial virus (RSV) prevention market with its antibody-based therapy Beyfortus, AstraZeneca has agreed to buy US biotech Icosavax and its phase 3 ...

Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion.